{
    "id": 30675,
    "fullName": "BRCA2 I1724T",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "BRCA2 I1724T lies within the POLH-interacting region of the Brca2 protein (UniProt.org). I1724T has been identified in the scientific literature (PMID: 29906251), but has not been biochemically characterized and therefore, its effect on Brca2 protein function is unknown (PubMed, Mar 2020).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 15905,
                    "pubMedId": 29906251,
                    "title": "Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29906251"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 675,
        "geneSymbol": "BRCA2",
        "terms": [
            "BRCA2",
            "BRCC2",
            "BROVCA2",
            "FACD",
            "FAD",
            "FAD1",
            "FANCD",
            "FANCD1",
            "GLM3",
            "PNCA2",
            "XRCC11"
        ]
    },
    "variant": "I1724T",
    "createDate": "08/05/2019",
    "updateDate": "03/05/2020",
    "referenceTranscriptCoordinates": {
        "id": 182219,
        "transcript": "NM_000059",
        "gDna": "chr13:g.32339526T>C",
        "cDna": "c.5171T>C",
        "protein": "p.I1724T",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17945,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Temodar (temozolomide) and Veliparib (ABT-888) combination treatment resulted partial response in a patient with small cell lung cancer harboring BRCA2 I1724T, with a progression-free survival of 6.0 months and an overall survival of 10.8 months (PMID: 29906251; NCT01638546).",
            "molecularProfile": {
                "id": 32907,
                "profileName": "BRCA2 I1724T"
            },
            "therapy": {
                "id": 1193,
                "therapyName": "Temozolomide + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15905,
                    "pubMedId": 29906251,
                    "title": "Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29906251"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32907,
            "profileName": "BRCA2 I1724T",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 182219,
            "transcript": "NM_000059",
            "gDna": "chr13:g.32339526T>C",
            "cDna": "c.5171T>C",
            "protein": "p.I1724T",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}